Avodart is the solution to combat prostate problems. These capsules contain dutasteride as an active ingredient and belong to the group of drugs known as anti-androgens (which will block the action of testosterone). As you know, the prostate is a gland located around the urethra and causes some problems when an enlarged prostate puts pressure on the urethra and bladder. All of this makes the urination process complicated. You may begin to experience these urinary symptoms: urine dripping after urination, intense need to urinate all the time, bladder control problems, incontinence and interrupted urinary flow. Avodart will reduce the prostate, eliminating pressure on the urethra. All of the urinary symptoms mentioned above will be reduced or even eliminated. A patient can reduce the prostate with Avodart Dutasteride easily.
Pharmacodynamics Dutasteride, an inhibitor of 5-a-reductase, inhibits isoenzymes type 1 and type 2 of the 5-a-reductase, which are responsible for the conversion of testosterone into 5-a-dihydrotestosterone. Dihydrotestosterone is an androgen, primarily responsible for prostate tissue hyperplasia. The maximum decrease in dihydrotestosterone while taking Avodart depends on the dose and is observed in the first 1-2 weeks. After the first and second weeks of treatment with Avodart at a daily dose of 0.5 mg, the average concentration of dihydrotestosterone decreases by 85 and 90%, respectively.
In patients with benign prostatic hyperplasia who received 0.5 mg of dutasteride per day, the average decrease in dihydrotestosterone level was 94% after 1 year and 93% after 2 years of treatment, the average testosterone level increased by 19% after 1 and 2 years. This is an expected consequence of inhibition of 5-A-reductase, and does not lead to the manifestation of several known side effects. According to the double-blind, placebo-controlled multicenter clinical trials, which included 4325 men with prostatic hyperplasia (>30 cm3), the use of Avodart at a dose of 0.5 mg/day led to disease progression prevention by reducing the risk of acute disease. urinary retention and the need for surgical intervention, and a statistically significant improvement in lower urinary tract state, an increase in urination rate and a decrease in prostate gland volume compared to placebo. All previous changes were observed for 24 months.
Pharmacokinetics. Dutasteride is administered orally as a solution in soft gelatin capsules. After taking a single dose of 0.5 mg Cmax of the drug in the blood plasma, it is observed after 1-3 hours. Absolute bioavailability is 60% and does not depend on food intake. Dutasteride after single or multiple uses has a large volume of distribution (300-500 l). Plasma protein binding -> 99.5%. When applied at a daily dose of 60%, a constant equilibrium concentration of dutasteride in the blood plasma is reached after 1 month of treatment and about 90% after 3 months. A constant dutasteride equilibrium concentration of approximately 40 ng/ml in blood plasma is achieved after 6 months of administration at a daily dose of 0.5 mg. Similarly, with blood plasma, a constant equilibrium concentration of dutasteride is reached in seminal fluid after 6 months. After 52 weeks of treatment, the average concentration of dutasteride in seminal liquid is 3.4 ng / ml (in the range of 0.4-14 ng / ml). The ratio of dutasteride distribution from blood plasma to seminal fluid is approximately 11.5%. In vitro, dutasteride is metabolized by human enzymes CYP 450 3A4 cytochrome P450 into two monohydroxylic metabolites. According to spectrometric analysis, unchanged dutasteride, 3 main metabolites (4-hydroxydutasteride, 1.2-dihydrorodutasteride and 6-hydroxydutasteride) and 2 small metabolites (6.4-dihydroxydydutasteride and 1.5-hydroxydutasteride) are detected in blood plasma. Dutasteride is extensively metabolised. After oral administration of dutasteride at a dose of 0.5 mg / day, 1-15.4% (on average 5.4%) is excreted in the faeces as unchanged dutasteride, the rest as metabolites. Unchanged traces of dutasteride are detected (<0.1%) in the urine. The final T1/2 of dutasteride is 3 to 6 weeks. Traces of dutasteride in the blood plasma can be detected 4-6 months after the end of treatment.
Indications Treatment and prevention of the progression of benign prostatic hyperplasia by reducing the size of the prostate gland, reducing the severity of symptoms of the disease, improving urine output, reducing the risk of acute urinary retention and, if necessary, surgical intervention. In combination with tamsulosin: treatment and prevention of progression of benign prostatic hyperplasia by reducing the size of the prostate gland, reducing the severity of disease symptoms and improving urine output. Request Avodart can be prescribed as monotherapy or in combination with the receptor blocker tamsulosin (0.4 mg). Adult men (including elderly patients) The recommended dose of Avodart is 1 capsule (0.5 mg) per day orally. The capsule swallows whole, does not open or chew, as contact with the contents of the capsule may irritate the mucous membrane of the oral cavity and pharynx. Buy Avodart UK for better results.
Avodart can be taken without regard to meals. Despite the fact that a decrease in the severity of the symptoms of the disease may be observed shortly after taking the drug, for an objective assessment of the effectiveness of the medicine, treatment continues for at least 6 months. For patients with renal impairment, no dose adjustment is necessary. Liver failure: The pharmacokinetics of dutasteride have not been studied in patients with hepatic impairment. Contraindications hypersensitivity to dutasteride, other inhibitors of 5-a-reductase or other components of the medicine. Severe liver failure. Avodart is not used in women and children. Side effects According to clinical trials, Avodart monotherapy, during therapy, the following adverse reactions were observed according to clinical trials with an onset frequency of 1% when using Avodart and placebo. Special instructions Dutasteride can be absorbed through the skin, so women and children should avoid contact with leaking capsules. If the capsule liquid comes into contact with the skin, it should be washed immediately with soap and water. The effect of hepatic impairment on the pharmacokinetics of dutasteride has not been studied. Since dutasteride is extensively metabolised and its T1/2 is 3 to 5 weeks, the drug is used with caution in liver disease. Buy Avodart Online to receive it at your doorstep.
Use in combination with tamsulosin. According to 4-year clinical studies, the incidence of heart failure was higher among patients treated with Avodart combination with adrenergic blockers, mainly tamsulosin, compared to patients who were not treated with this combination. According to 2 studies, the rate of heart failure was low (1%) variable within these studies. There were no imbalances in the incidence of cardiovascular side effects in any of the studies. A causal relationship has not been established between the use of Avodart (alone or in combination with adrenergic blockers) and the onset of heart failure. Effect on PSA and screening for prostate cancer Before starting treatment with sweettasteride and periodically during treatment, a digital rectal examination of the patient and other studies should be performed to detect prostate cancer. PSA concentration is an important component of a screening method for detecting prostate cancer. Treatment with Avodart may reduce the level of PSA in plasma with benign prostatic hyperplasia by approximately 50% after 6 months of treatment. Patients receiving Avodart should have a new initial PSA level established after 6 months of treatment with the drug. It is recommended to check PSA levels regularly. Any sustained increase in PSA compared to minimum values during treatment with Avodart may indicate the presence of prostate cancer (especially high-degree malignancy cancer) or lack of adherence to the Avodart regimen and should be carefully studied, even if PSA values are within the normal range for men, who were not treated with 5-S-reductase inhibitors. The use of Avodart does not affect the use of PSA levels for prostate cancer diagnosis after setting its new reference value. According to a 4-year clinical study involving patients at increased risk of prostate cancer, an increase in PSA after establishing its new value (after 6 months of treatment) is more informative (especially for high-grade malignancy cancer) in men treated with Avodart. compared to taking a placebo. The total serum PSA level returns to the baseline for 6 months after discontinuation of treatment. The relationship between free PSA and total PSA remains constant even during treatment with Avodart. Therefore, when using the percentage of free PSA in a patient taking Avodart to diagnose prostate cancer, the value of free PSA should not be duplicated.
Fertility. A study on the effect of dutasteride at a dose of 0.5 mg/day on ejaculation characteristics in 27 healthy volunteers during 52 weeks of treatment and 24 weeks of follow-up revealed a decrease in total sperm count, ejaculation volume and sperm motility at 23; 26 and 18% compared to changes in the placebo group. The concentration and morphology of sperm remained unchanged. After 24 weeks of follow-up, the average percentage of changes in total sperm count in the dutasteride group remained 23% below the initial value. While the average values for all sperm parameters in all periods remained within normal limits and did not meet certain criteria for clinically significant changes (30%), in 2 patients in the dutasteride group, A decrease in sperm count was observed by more than 90% compared to the initial level at 52 weeks of treatment and a partial restoration of its number after 24 weeks of subsequent observation. The clinical significance of the effect of dutasteride on sperm characteristics for fertility of individual patients is unknown. During pregnancy and lactation Dutasteride is contraindicated for use in women. The use of dutasteride for the treatment of women has not been studied as, according to preclinical studies, it was suggested that a decrease in the level of circulating dihydrotestosterone may lead to impaired development of the external genital organs in the male fetus. Children Use is contraindicated. The ability to influence the speed of reaction when driving vehicles or other mechanisms. Given the pharmacokinetic and pharmacodynamic properties, dutasteride does not affect the ability to drive a car and other mechanisms.
Interactions Since CYP 3A4 isoenzyme metabolizes dutasteride, the plasma concentration of dutasteride may increase in the presence of CYP 3A4 inhibitors, and dutasteride clearance decreases with the use of verapamil (37%) diltiazem (44%) CYP 3A4 inhibitors. However, dutasteride clearance does not decrease when used with another calcium channel antagonist, amlodipine. A decrease in clearance and a corresponding increase in the severity of the action of dutasteride in the presence of CYP 3A4 inhibitors is not of great clinical importance due to the wide range of safety of the medicinal products. CYP 1A2, CYP 2C9, CYP2 C19 and CYP 2D6 isoenzymes are not involved in the metabolism of dutasteride in humans, dutasteride does not inhibit cytochrome P450 system enzymes in humans involved in drug metabolism. In vitro studies have shown that dutasteride does not displace warfarin, diazepam or phenytoin from its association with blood plasma proteins, as well as these components do not replace dutasteride. The interaction of dutasteride with tamsulosin, teazosine, warfarin, digoxin and cholestyramine was studied. No clinically significant interaction was detected. Although no specific studies have been conducted to study interaction with other medicinal products, approximately 90% of all patients in clinical studies of dutasteride received another concomitant therapy. No clinically significant adverse reactions were observed with the simultaneous use of dutasteride with antihyperlipidic drugs, ACE inhibitors, adrenergic blockers, calcium channel blockers, GCS, diuretics, NSAIDs, type V PDE inhibitors and quinolone antibiotics. According to a study on the interaction of tamsulosin or terazosine in combination with Avodart for 2 weeks, no signs of pharmacokinetic or pharmacodynamic interaction were detected.
Overdose According to clinical studies, in volunteers, a single dose of dutasteride of up to 40 mg / day (80 times the therapeutic dose) for 7 days did not cause undesirable manifestations, taking into account the safety of its use. In clinical studies, a dutasteride dose of 5 mg/day was used for 6 months with no additional adverse reactions compared to the use of dutasteride at a dose of 0.5 mg/day. There is no specific antidote, therefore, in case of a possible overdose, symptomatic therapy is performed. Buy Dutasteride to experience better results.